DrugPatentWatch Database Preview
Drugs in Development Information for TAK-438
» See Plans and Pricing
What is the drug development status for TAK-438?
TAK-438 is an investigational drug.
There have been 348 clinical trials for TAK-438.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are eighteen US patents protecting this investigational drug and one hundred and sixty-four international patents.
Summary for TAK-438
US Patents | 18 |
International Patents | 164 |
US Patent Applications | 30 |
WIPO Patent Applications | 9 |
Japanese Patent Applications | 1 |
Clinical Trial Progress | Phase 3 (2018-01-01) |
Vendors | 67 |
Recent Clinical Trials for TAK-438
Title | Sponsor | Phase |
---|---|---|
A Study of TAK-994 in Adults With Narcolepsy | Takeda | Phase 2 |
Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults | Takeda | Phase 1 |
Bioavailability and Food Effect Study of Two Formulations of TAK-906 | Takeda | Phase 1 |
Clinical Trial Summary for TAK-438
Top disease conditions for TAK-438
Top clinical trial sponsors for TAK-438
US Patents for TAK-438
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
TAK-438 | Start Trial | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | Takeda Pharmaceutical Company Limited (Osaka-Shi, JP) | Start Trial |
TAK-438 | Start Trial | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
TAK-438 | Start Trial | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-438
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
TAK-438 | China | CN102421753 | 2029-02-25 | Start Trial |
TAK-438 | China | CN104211618 | 2029-02-25 | Start Trial |
TAK-438 | China | CN105524046 | 2029-02-25 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |